Stamford, CT; October 3, 2024 – ApiJect Systems, Corp. a medical technology company whose device development platform will make the safety and performance advantages of single-use prefilled syringes affordable and available for many more patients in the U.S. and globally, announced today the promotion of Molly Weaver, Ph.D. to the position of Chief Operating Officer.
“This promotion reflects the central role Molly now plays in corporate strategy and business operations,” said Jon Ellenthal, President, ApiJect Systems. “Molly combines deep technical expertise with the business acumen, communication, and critical thinking skills needed to deliver on the full promise of our technology and team. With Molly serving as the Company’s Chief Operating Officer, ApiJect is in an even stronger position to transform how injectable medicines and vaccines are filled, finished, and delivered.”
“I am pleased with the significant progress we have made on the ApiJect Platform and excited to continue driving the transformation in injection medicine led by our company,” said Molly Weaver, Ph.D. “We successfully have completed material and process compatibility studies for over 10 different drugs and vaccines, covering a variety of molecule types. Additionally, we’ve partnered to repackage on-market therapeutics into our unit-dose prefilled system up to 1 milliliter, suitable for intramuscular and subcutaneous administration.”
Dr. Weaver continued: “Our device development services have helped design injector systems tailored for specific therapies, markets, and users. We are currently engaged in projects within commercial pharmaceutical markets, global health initiatives, and collaborations supporting the health policy goals of the U.S. Government. I am pleased to note that ApiJect will be filing our first FDA regulatory submission within the next few months.”
Dr. Weaver is a seasoned industry leader whose background includes pharmaceutical and medical technology. Her leadership and expertise spans strategy, product development, and execution across a broad range of industrialization and drug delivery systems. Most recently, Dr. Weaver was Chief Technology Officer at ApiJect. Her responsibilities have included the development of ApiJect’s Blow-Fill-Seal injection devices and production of its initial device, a single-dose prefilled drug delivery system. She has led a dynamic team that aims for innovation in new design and continuous improvement on existing devices. Previously, she served as Vice President for Containment Systems & Portfolio Management at West Pharmaceutical Services where she was responsible for elastomer and container R&D, product packaging and sterilization, and management of more than 30 projects across the full West portfolio of work, including partnership with commercial fill-finish operations. She previously worked at Becton Dickinson & Company and Unilife Medical Corporation. Dr. Weaver holds a Ph.D. in Mechanical Engineering Materials Science from Duke University and has published research in top journals in her field.
ABOUT APIJECT SYSTEMS, CORP.
ApiJect Systems, Corp. is a public-benefit medical technology company that has pioneered a new category of prefilled injection devices with economic, supply chain, and sustainability advantages over traditional offerings. Our mission is to make the safety and performance benefits of prefilled injections affordable and available for most, if not all, injections around the world. The Company’s technology platform is anchored by a well-established manufacturing process called Blow-Fill-Seal (BFS”). BFS is a widely used sterile liquid packaging technology that has been recognized by the FDA as an advanced aseptic process.
For more information on ApiJect, visit www.apiject.com.
Contacts: Kate Scott, [email protected] and Steve Hofman, [email protected]